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Just like the gold rush back in the 1840s, people 
fawn over stem cells, which are thought to be 
the potential miracle drug for Alzheimer’s 
disease, spinal cord injuries, heart disease, and 
other diseases. The earliest developed stem cell 
and the most efficient one to produce is the 
embryonic stem cell. Many research in 
embryonic stem cells have reached the clinical 
trial phase, with mixed results for success rate. 
Despite the questionable efficacy of embryonic 
stem cell therapy, many people are willing to 
use that option with extravagant cost. 
Throughout the years however, the spotlight has 
shifted towards a new type of stem cells; the 
induced pluripotent stem cells (iPS Cells). One 
significant reason why this new type is highly 
favorable is the fact that producing it does not 
require the “killing” of embryos, thus 
eliminating the legal issues of conducting the 
research. There are, of course, downsides of iPS 
Cells compared to ES Cells, they are its very 
low efficiency and success rate of producing 
viable pluripotent stem cells, its potential to 
form tumors, and ironically the rising ethical 
issues related to iPS cells research and clinical 
application.  
The problem with low success rate can be 
caused by several theories. The first theory is 
that the starting cell population is a mixture of a 
myriad of cell types. For example, the chunk of 
tissue to derive fibroblasts could contain a mix 
of subtly different cell types; even those that are 
fibroblasts will differ slightly in the mixture of 
proteins and other molecules they contain. In 
addition, cells that are grown in culture 
constantly shuttle back and forth between 
different states, which mean that the introduced 
reprogramming factors will affect each cell 
differently. Scientists are now trying to classify 
some of the cell types and working with 
reprogramming techniques to observe how and 
where they diverge. 
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In general there are two theories that might 
explain why iPS cells may form tumors. One is 
that iPS cells, in response either to reactivation 
of the reprogramming factors introduced into the 
cell, or through damage caused to the original 
cell genome through the artificial insertion of 
the reprogramming factors, form tumors. The 
second theory is that the remains of 
undifferentiated cells or other factors lead to the 
formation of teratomas. A potential solution for 
this would be to increase the iPS cell 
proliferation and differentiation and tumor 
formation using optimal reprogramming factors 
and optimal vectors. 
 
One ethical issue that is applied to ES Cells is 
also used against iPS cells, which is the scenario 
evocative of science fiction; although iPS cells 
don’t come from embryos, a scientist could 
induce the infinitely versatile cells to form 
sperm and eggs, and they might even cross the 
gametes in a laboratory dish to study aspects of 
human genetics. In addition, there is also the 
possibility of introducing human iPS cells into 
an embryo from a mouse or other animal, giving 
rise to a human-mouse chimera.  
The donors of iPS cells could also face ethical 
issues regarding consent of the usage of their 
cells for a variety of research projects as well as 
the risk of having the donor’s genetic 
information to be disclosed to the public, which 
incurs violating the donors’ privacy. However 
possible the scenarios of science fiction are, the 
process of conducting research with that goal set 
in mind is too unlikely. For one, finding 
someone who would fund such research will be 
very difficult, and without funding automatically 
the research would come to a halt as well; thus 
preventing the scenario to happen. Another 
problem would be just having the idea of 
conducting such research is a very far out 
possibility. Researchers do not work on any 
topic they want, there are many considerations, 
with the lack of support and profit from 
conducting bizarre research as examples. As for 
issues concerning the donor, there are many 
ways to work around it, such as by having a 
scrutinized surveillance in the research process, 
and for certain cases, have the donor for the iPS 
cell the patients themselves.  
 
Based on these points, there are still ways that 
the issues of iPS cells can be overcome.The 
potential threat of ethical issues for the clinical 
application and study in iPS cells can also be 
diminished. Even if there could be other new 
issues that will be brought up, the main ethical 
issue that ES Cells are stuck with has been 
removed; therefore giving iPS cells a potential 
regenerative medicine that could be safely, 
widely and effectively used for everyone. 
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